## BAX: Baxter International Inc. - XLV: Healthcare

### Executive Summary

No thesis match: PEG 35.49 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($18.05)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 1, Bearish: 9)

**1. BAX Highlights EMR-Integrated Smart Pumps Boost Patient Safety & Care**
- Source: TradingView — Track All Markets | 20251215T150752 | Bullish | Relevance: 100%
- Baxter International Inc. (BAX) recently presented real-world data at the ASHP 2025 Midyear Clinical Meeting, showcasing the benefits of integrating smart infusion pumps with hospital EMRs. The data, gathered from over one million IV infusions using Baxter’s Spectrum IQ pumps, demonstrated reductions in patient safety alerts, shorter infusion programming times, and improved clinician productivity. These findings support the long-term growth of BAX by highlighting enhanced patient safety and nursing efficiency through connected infusion technologies.

**2. SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Baxter International Inc. with Losses of $100,000 to Contact the Firm**
- Source: PR Newswire | 20251215T071239 | Bearish | Relevance: 100%
- The Schall Law Firm is encouraging investors of Baxter International Inc. who experienced losses of $100,000 or more to contact them regarding a class action lawsuit. The lawsuit alleges that Baxter made false and misleading statements about its supply chain issues between May 25, 2022, and February 8, 2023. Investors are urged to participate before September 11, 2023, to potentially recover damages.

**3. BAX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Baxter International, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit**
- Source: WLNS 6 News | 20251214T170741 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Baxter International, Inc. on behalf of investors who purchased securities between February 23, 2022, and October 29, 2025. The lawsuit alleges that Baxter misled investors by failing to disclose systemic defects in its Novum LVP medical devices, which caused malfunctions and patient harm. Investors suffering losses have until December 15, 2025, to request to be appointed as lead plaintiff.

**4. Class Action Alert: Levi & Korsinsky Reminds Baxter International, Inc. (BAX) Investors of December 15, 2025 Deadline**
- Source: WJTV | 20251214T160741 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP reminds investors of Baxter International, Inc. (NYSE: BAX) about a class action lawsuit deadline on December 15, 2025. The lawsuit alleges that Baxter made false statements regarding defects in its Novum LVP product, leading to investor losses. Shareholders affected between February 23, 2022, and October 29, 2025, are encouraged to seek information on potential recovery.

**5. BAX DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Baxter Investors Have Opportunity to Lead Class Action Lawsuit**
- Source: TMX Newsfile | 20251214T140758 | Bearish | Relevance: 100%
- Faruqi & Faruqi, LLP has announced that Baxter International Inc. (NYSE: BAX) investors who suffered losses between February 23, 2022, and October 29, 2025, have the opportunity to lead a class action lawsuit. The lawsuit alleges that Baxter made false or misleading statements regarding systemic defects in its Novum LVP medical devices, which caused widespread malfunctions and patient harm. Investors have until December 15, 2025, to seek the role of lead plaintiff.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $15 | $19 | -21% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Blackrock Inc.: 15.1% (+14.9%)
- Vanguard Group Inc: 12.2% (+0.5%)
- Dodge & Cox Inc.: 11.2% (+10.1%)
- Pzena Investment Man: 11.2% (+45.9%)
- State Street Corpora: 4.3% (+0.3%)

### Key Risks

1. Valuation stretched: PEG 35.5x requires aggressive growth execution.
2. Elevated short interest (9.7%): bears positioning against stock.
3. Long-term trend broken: trading 27.9% below SMA200.

### Catalysts

- Momentum building: MRS_10 improving +7.5% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 35.49 signals overvaluation risk, limited margin of safety. Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.8B |
| Beta | 0.61 |
| 52W Range | $17.40 - $37.74 |
| Short Interest | 9.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 35.49 |
| Forward P/E | 8.3 |
| Current P/E | 8.1 |
| YoY Growth | -2.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.5% to 4.0% (+7.5% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 75th percentile. MRS_5 at 4.8% confirms short-term momentum alignment. Outperforming sector by 4.2pp, stock-specific strength. Below SMA200 (0.72x), long-term trend not supportive. RSI neutral at 52. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.95% (CS: 76) | Strong |
| RSI_14 | 52.5 | Neutral |
| MACD Histogram | 0.18 | Bullish |
| vs SMA20 | 1.039x | Above |
| vs SMA50 | 0.954x | Below |
| vs SMA200 | 0.721x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $19.15
- **Stop Loss:** $18.05 (5.7% risk)
- **Target:** $20.25 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 909
- **Position Value:** $17,407.35
- **Portfolio %:** 17.41%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-19 (Est: $0.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.60 | $0.69 | +15.4% |
| 2025Q2 | $0.61 | $0.54 | -11.5% |
| 2025Q1 | $0.48 | $0.55 | +13.8% |
| 2024Q4 | $0.53 | $0.58 | +9.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*